albumin - publications

Predict more albumin - ligand interactions now!


1. Pathol Oncol Res. 2012 Feb 8. [Epub ahead of print]

The Albumin and Monoclonal Protein Ratio as Prognostic Marker for Multiple
Myeloma in the Era of Novel Agents.

Kádár K, Wolf K, Tábori J, Karádi I, Várkonyi J.

Kútvölgyi Clinical Centre, Semmelweis University, Kútvölgyi út 4., 1125,
Budapest, Hungary, kadarka@kut.sote.hu.

Multiple myeloma (MM) is a heterogeneous disease group regarding prognosis,
clinical course, and response to therapeutic interventions. Numerous prognostic
factors have been identified however there was no consensus about the best
prognostic indicators or the proper staging systems. In a previous study the A/M
ratio containing albumin (A) and monoclonal component (M) emerged as reliable
predictor of survival duration in patients treated with conventional
chemotherapy. In the current retrospective study authors evaluated the prognostic
role of this fraction in the era of novel agents. They assessed the A/M ratio
prior treatment in 56 newly diagnosed MM patients from the aspect of the survival
time. According to the results the A/M being <1 at the diagnosis indicated
significantly poorer prognosis both at the 2 years (p = 0,01) and at the 5 years
(p = 0,07) survival endpoints. These results proved that A/M ratio remained
valuable marker for predicting prognosis in patients treated with proteosome
inhibitor and antiangiogenic therapy as well. Authors recommend therefore
applying this A/M ratio in further studies for the better pre-treatment
stratification.

PMID: 22314327 [PubMed - as supplied by publisher]